Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

Connie A. Sizemore, Pharm.D., Karen Manion, RN, Lawrence Morris, MD, Asad Bashey, MD, PhD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2010) 116 (21): 3525.

https://doi.org/10.1182/blood.V116.21.3525.3525

Published: 2010

Journal Articles

Improved Survival using Dual Monoclonal Antibody Therapy with Aggressive Anti-Microbial Prophylaxis In Steroid-Refractory Acute Graft-Versus-Host Disease

Melissa Sanacore, PharmD, Karen Manion, RN, Pauline Smith, RN, Xu Zhang, PhD, H. Kent Holland, MD, Lawrence Morris, MD, Scott R. Solomon, MD, Asad Bashey, MD, PhD

Blood (2010) 116 (21): 1262.

https://doi.org/10.1182/blood.V116.21.1262.1262

Published: 2010

Journal Articles

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Steven D. Gore, MD, Lawrence Morris, MD, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Mikkael A. Sekeres, MD, MS, Robert J. Arceci, MD, PhD, Robert L. Redner, MD, Tianna Dauses, BSN, Esther L Schachter-Tokarz, Ibitayo Owoeye, MD, Robert E. Gallagher, MD

Blood (2008) 112 (11): 1932.

https://doi.org/10.1182/blood.V112.11.1932.1932

Published: 2008

Journal Articles

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Judith E. Karp, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Jacqueline Greer, RN, Valerie Ironside, RN, B. Douglas Smith, MD, Ellen Ritchie, MD, Steven D. Gore, MD, Mark J. Levis, MD,PhD, Scott H. Kaufmann, MD,PhD, Sami Malek, MD, John J. Wright, MD,PhD

Blood (2006) 108 (11): 426.

https://doi.org/10.1182/blood.V108.11.426.426

Published: 2006

Journal Articles

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Judith E. Karp, MD, Ivana Gojo, MD, Jacqueline Greer, R.N., B. Douglas Smith, MD, Maureen Klein, R.N., Jeffery E. Lancet, MD, Steven D. Gore, MD, Lawrence Morris, MD, Alain Thibault, MD, Mary Ellen Rybak, MD, John J. Wright, MD, PhD

Blood (2005) 106 (11): 2783.

https://doi.org/10.1182/blood.V106.11.2783.2783

Published: 2005

Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD

Blood (2004) 104 (11): 874.

https://doi.org/10.1182/blood.V104.11.874.874

Published: 2004

Journal Articles

Phase II Study of Timed Sequential Therapy (TST) with Topotecan, Cytosine Arabinoside (ARA-C), and Mitoxantrone (TAM) Induction Therapy Followed by Non-Cross-Resistant Consolidation Chemotherapy for Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Ivana Gojo, MD, Lawrence Morris, MD, Chuanfa Guo, PhD, Meyer Heyman, MD, Michael Tidwell, NP, Jackie Greer, RN, Maureen Klein, RN, Marianne Irani, PharmD, Judith Karp, MD

Blood (2004) 104 (11): 876.

https://doi.org/10.1182/blood.V104.11.876.876

Published: 2004

NARROW

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care

Improved Survival using Dual Monoclonal Antibody Therapy with Aggressive Anti-Microbial Prophylaxis In Steroid-Refractory Acute Graft-Versus-Host Disease

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Tipifarnib (Zarnestra, R115777) as Maintenance Therapy for Adults in Complete Remission (CR) Following Induction and Consolidation Therapies for Poor-Risk Acute Myelogenous Leukemia (AML): A Phase II Trial.

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Phase II Study of Timed Sequential Therapy (TST) with Topotecan, Cytosine Arabinoside (ARA-C), and Mitoxantrone (TAM) Induction Therapy Followed by Non-Cross-Resistant Consolidation Chemotherapy for Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only